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Undiagnosed HIV infection remains substantial in key population subgroups including ado-
lescents, older adults, and men, driving ongoing transmission in sub-Saharan Africa. We
evaluated the impact, safety, and costs of community-led delivery of HIV self-testing
(HIVST), aiming to increase HIV testing in underserved subgroups and stimulate demand
for antiretroviral therapy (ART).
Methods and findings
This cluster-randomised trial, conducted between October 2018 and July 2019, used
restricted randomisation (1:1) to allocate 30 group village head clusters in Mangochi district,
Malawi to the community-led HIVST intervention in addition to the standard of care (SOC) or
the SOC alone. The intervention involved mobilising community health groups to lead the
design and implementation of 7-day HIVST campaigns, with cluster residents (�15 years) eli-
gible for HIVST. The primary outcome compared lifetime HIV testing among adolescents (15
to 19 years) between arms. Secondary outcomes compared: recent HIV testing (in the last 3
months) among older adults (�40 years) and men; cumulative 6-month incidence of ART ini-
tiation per 100,000 population; knowledge of the preventive benefits of HIV treatment; and
HIV testing stigma. Outcomes were measured through a post-intervention survey and at
neighboring health facilities. Analysis used intention-to-treat for cluster-level outcomes.







Citation: Indravudh PP, Fielding K, Kumwenda MK,
Nzawa R, Chilongosi R, Desmond N, et al. (2021)
Effect of community-led delivery of HIV self-testing
on HIV testing and antiretroviral therapy initiation in
Malawi: A cluster-randomised trial. PLoS Med
18(5): e1003608. https://doi.org/10.1371/journal.
pmed.1003608
Academic Editor: Matthew P. Fox, Boston
University, UNITED STATES
Received: August 3, 2020
Accepted: April 4, 2021
Published: May 11, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pmed.1003608
Copyright: © 2021 Indravudh et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Primary data are
available at https://doi.org/10.17037/DATA.
00001971.
Community health groups delivered 24,316 oral fluid-based HIVST kits. The survey
included 90.2% (3,960/4,388) of listed participants in the 15 community-led HIVST clusters
and 89.2% (3,920/4,394) of listed participants in the 15 SOC clusters. Overall, the proportion
of men was 39.0% (3,072/7,880). Most participants obtained primary-level education or
below, were married, and reported a sexual partner. Lifetime HIV testing among adoles-
cents was higher in the community-led HIVST arm (84.6%, 770/910) than the SOC arm
(67.1%, 582/867; adjusted risk difference [RD] 15.2%, 95% CI 7.5% to 22.9%; p < 0.001),
especially among 15 to 17 year olds and boys. Recent testing among older adults was also
higher in the community-led HIVST arm AU : Anabbreviationlisthasbeencompiledforthoseusedinthetext:Pleaseverifythatallentriesarecorrect:(74.5%, 869/1,166) than th SOC arm (31.5%, 350/
1,111; adjusted RD 42.1%, 95% CI 34.9% to 49.4%; p < 0.001). Similarly, the proportions of
recently tested men were 74.6% (1,177/1,577) and 33.9% (507/1,495) in the community-led
HIVST and SOC arms, respectively (adjusted RD 40.2%, 95% CI 32.9% to 47.4%; p <
0.001). Knowledge of HIV treatment benefits and HIV testing stigma showed no differences
between arms. Cumulative incidence of ART initiation was respectively 305.3 and 226.1 per
100,000 population in the community-led HIVST and SOC arms (RD 72.3, 95% CI −36.2 to
180.8; p = 0.18). In post hoc analysis, ART initiations in the 3-month post-intervention period
were higher in the community-led HIVST arm than the SOC arm (RD 97.7, 95% CI 33.4 to
162.1; p = 0.004). HIVST uptake was 74.7% (2,956/3,960), with few adverse events (0.6%,
18/2,955) and at US$5.70 per HIVST kit distributed. The main limitations include the use of
self-reported HIV testing outcomes and lack of baseline measurement for the primary
outcome.
Conclusions
In this study, we found that community-led HIVST was effective, safe, and affordable, with
population impact and coverage rapidly realised at low cost. This approach could enable
community HIV testing in high HIV prevalence settings and demonstrates potential for econ-




Why was the study done?
• Prevalence of undiagnosed HIV infection is significant in adolescents, older adults, and
men, with alternative HIV testing strategies needed to reach underserved population
subgroups.
• The aim of the study was to evaluate whether community-led delivery of HIV self-test-
ing (HIVST) increased HIV testing in underserved population subgroups and antiretro-
viral therapy (ART) initiations, how safely, and with what costs.
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What did the researchers do and find?
• We conducted a cluster-randomised trial in a rural, high HIV prevalence area of
Malawi, randomising group village head clusters to the community-led HIVST inter-
vention or standard of care (SOC) arms.
• The intervention involved mobilising established community health groups to lead the
design and implementation of 7-day HIVST campaigns in addition to the SOC, which
primarily included facility-based HIV testing services. Outcomes were assessed through
a post-intervention survey and at neighbouring health facilities.
• The survey included 7,880 participants. Following delivery of community-led HIVST,
lifetime testing increased by 15.2% for adolescents and recent testing increased by
42.1% for older adults and by 40.2% for men. Cumulative incidence of ART initiation
apparently increased 3 months post-intervention, with difference between arms of 97.7
residents treated per 100,000 population.
• Uptake of HIVST was 74.7%, with limited adverse events and at US$5.70 per HIVST kit
distributed.
What do these findings mean?
• Community-led HIVST rapidly achieved high impact on HIV testing and ART initia-
tion and high coverage of HIVST at low cost.
• National HIV programmes in priority settings should consider community-led HIVST
for periodic community HIV testing to achieve HIV elimination goals. This approach
has potential for further economies of scale and scope, with community health groups
widely established throughout sub-Saharan Africa and increasing availability of self-care
products.
IntroductionAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Theheadingsaredesignatedbyfontsize;withsize14   pointfontbeingthetopheadinglevelinthebodyofthemanuscript; followedby12   pointfont:
In 2018, approximately 1.7 million people were newly infected with HIV, with most cases in
sub-Saharan Africa [1]. Regionally, almost one-fifth of people living with HIV were unaware
of their HIV status [1]. Gaps remain more substantial among adolescents 15 to 19 years, older
adults 40 years and above, and men [2]. While HIV incidence has been declining, undiagnosed
HIV infection in these key population subgroups are drivers of ongoing transmission, imped-
ing achievement of HIV elimination goals [1]. Routine HIV testing is a critical component of
providing early diagnosis and treatment to reduce HIV-related morbidity and mortality and
maximise HIV prevention benefits [3].
HIV testing services (HTS) are being provided within the context of declining undiagnosed
HIV [4]. Most HTS are facility-based, though barriers including HIV-related stigma and dis-
crimination, lack of convenience, and economic costs for clients have hindered uptake among
underserved subgroups [5,6]. Community-based HTS can diagnose individuals at earlier
stages of disease [7] and improve treatment and viral suppression when combined with conve-
nient antiretroviral therapy (ART) services [8]. Despite their contributions, costs are higher
for community-based HTS and global funding for community health programmes has been
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declining [7,9]. More efficient and scalable community strategies are needed to reach and
maintain universal HIV testing in HIV-prevalent populations.
Among the most promising approaches are community-led strategies for disease preven-
tion and management, which aim to involve underserved communities in decision-making,
align health programmes with community-specific needs and experiences, and expand and
sustain coverage [10]. Prior studies have shown increased coverage and efficiency and
improved health outcomes when communities participate in the design and implementation
of health services [11–14]. Within HIV, community groups have led demand creation activities
for HIV services [12,15]. Recent innovations in self-care technologies are now expanding the
breadth of services that could be delivered by communities [16].
HIV self-testing (HIVST) is a recommended approach that can facilitate novel HIV testing
strategies [17]. Previous studies have demonstrated the effectiveness of door-to-door distribution
of HIVST kits on increased HIV testing in Malawi and Zambia [18,19]. Given the impact of verti-
cal community-based HIVST, we evaluated community-led delivery of HIVST. Specifically, we
investigated the impact, safety, and costs of mobilising community health groups to lead the
design and implementation of 7-day HIVST campaigns, aiming to increase HIV testing in under-
served subgroups and stimulate demand for ART in a rural, high HIV prevalence area of Malawi.
Methods
Design
We conducted a cluster-randomised trial and allocated 30 group village head clusters to the
community-led HIVST intervention in addition to the standard of care (SOC) or the SOC
alone (S1 CONSORT Checklist). A cluster-randomised design was used since the intervention
was delivered at group village head level. The study aimed to determine whether the interven-
tion increased the proportion of the population who tested for HIV at cluster level, focusing
on adolescents, older adults, and men. The trial also assessed impacts on population-level ART
initiation, knowledge of the preventive benefits of HIV treatment, and HIV testing stigma;
adverse events; and costs. A detailed protocol was published separately [https://hivstar.lshtm.
ac.uk/protocols/] [20].
Setting and participants
Mangochi is a rural district bordering Lake Malawi and Mozambique with adult HIV preva-
lence of 10.1% (Fig 1) [21]. Group village heads hold customary authority over a group of vil-
lages. Government community health workers (CHWs) oversee provision of basic health
services with community health action groups at the group village head level. Community vol-
unteers, including village health committees, provide services at village level.
Group village head clusters serviced by 5 government primary health centres were assessed
by the study team for eligibility. Clusters were defined according to the boundaries of the
group village head catchment area. Inclusion criteria for clusters prioritised a minimum popu-
lation of 2,000 residents, distance of at least 5 kilometres to the health facility, and geographical
separation between clusters. The study team obtained verbal consent from group village heads
for cluster enrolment.
Randomisation
The 30 group village head clusters were randomised (1:1) to the community-led HIVST or
SOC arm. Restricted randomisation was used to ensure balance between arms for key factors
that could influence the effect of the intervention [22]. Restriction criteria included health
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facility, population, distance from facility, and number of villages (S1 Text). From 12,540
unique combinations falling within the restriction parameters, PPI and KF drew a computer-
generated random sample of 1,000 combinations, which were sequentially numbered.
On July 16, 2018, group village head clusters were randomised at a public ceremony with
community and government representatives. Volunteers selected numbered balls correspond-
ing to one combination and one arm allocation from an opaque bag. Masking of community
implementers and residents was not feasible since the intervention was delivered at cluster
level, but data were managed and analysed without reference to arm allocation where possible.
Procedures
Community-led HIV self-testing
The community-led HIVST intervention involved engaging established community health
groups from 15 group village head clusters to lead the design and implementation of HIVST
Fig 1. Map of clusters in Mangochi district. HIVST, HIV self-testing; SOC, standard of care. Map of Mangochi district with health
facilities and group village head-defined clusters. Malawi National Spatial Data Centre, www.masdap.mw.
https://doi.org/10.1371/journal.pmed.1003608.g001
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campaigns in their areas. Implementation was staggered, with 2 to 3 clusters receiving the
intervention every 14 days. Implementation was administered by the study team, including
Population Services International Malawi, the Malawi-Liverpool-Wellcome Trust Clinical
Research Programme, and the Ministry of Health. Formative research and piloting informed
the design [20].
Following entrance meetings, the intervention proceeded in 3 stages, adapting participatory
learning and action methods [23]. First, community health action groups and CHWs attended
2-day participatory workshops. Participants identified drivers of HIV infection, mapped HIV
services and barriers to access, defined priority subgroups, and designed a 7-day HIVST cam-
paign to be delivered in their areas. Specifically, participants planned strategies for distribution
of HIVST kits, support for linkage to routine HIV care, demand creation for HIVST, social
harms reporting, and monitoring and evaluation.
Second, community volunteers attended 2-day trainings on supporting use and interpreta-
tion of HIVST kits and providing information on linkage to routine HIV services, specifically
confirmatory testing and ART initiation for reactive results, voluntary medical male circumci-
sion (VMMC) for nonreactive results among men, and couples testing for serodiscordant
results among partners. Volunteers were also trained on communication of HIV prevention
messages, including effectiveness of ART, management of social harms, handling and storage
of kits, and data collection.
Lastly, community volunteers delivered the campaign in their areas, supervised by commu-
nity health action groups and CHWs. Implementation was based on strategies defined during
participatory workshops for each cluster. HIVST sensitisation and distribution was conducted
door-to-door and from fixed locations (e.g., schools, mosques, boreholes), social hotspots (e.g.,
fishing docks, sports fields, video shows), and community meetings. Support for linkage to
routine services provided by community health groups included phone referrals and donated
transportation funds. In addition to support provided by communities, the study team sup-
plied the OraQuick HIV Self-Test (Orasure Technologies, Thailand), instructional materials,
data collection tools, and nationally standardised gratuity of MWK 7,000 (US$10) per volun-
teer. HIVST kits could be taken by cluster residents aged 15 years and older. Residents could
take an additional kit for secondary distribution and self-test with volunteer support or in pri-
vate, with or without disclosing results.
Standard of care
The SOC, which was also available in community-led HIVST clusters, included HIV testing
available through the Ministry of Health. HTS are provided by lay counsellors at health facili-
ties through periodic community-based outreach. HIV testing follows standard serial testing
algorithms using finger-prick rapid diagnostic tests, with ART universally available immedi-
ately following an HIV-positive diagnosis.
Outcomes and measurement
Outcomes were selected to understand the effect of the intervention on uptake of HIV services,
especially among low-coverage subgroups. The primary outcome compared the proportion of
adolescents (15 to 19 years) who self-reported lifetime testing for HIV between arms. Lifetime
testing was a more relevant measure for adolescents since we anticipated that a high proportion
of adolescents would have never tested [21], with the need for testing among this age group
highly variable and dependent on the onset of sexual debut and HIV risk. We therefore
hypothesised that the intervention would increase coverage of lifetime testing in a subgroup
with limited previous experience of HIV testing, with a similar effect achieved on recent testing.
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Secondary outcomes compared: self-reported recent HIV testing (in the last 3 months)
among older adults (�40 years) and men; cumulative 6-month incidence of ART initiation
per 100,000 population; knowledge of the preventive benefits of HIV treatment; and HIV test-
ing stigma. Exploratory outcomes compared: mutual knowledge of HIV status between sexual
partners; recent HIV testing for adolescents; lifetime HIV testing for older adults and men;
and HIV testing in the last 12 months for adolescents, older adults, and men. Cumulative inci-
dence of VMMC was not assessed as specified in the protocol as services were discontinued
prior to study initiation.
Outcomes were measured at cluster level through a post-intervention survey, except for ART
initiations, which were captured at the 5 health facilities. The survey was administered 8 to 12
weeks after the intervention start in the community-led HIVST clusters or matched dates in the
SOC clusters. Cluster residents were sampled for the survey to form the evaluation population.
Within each cluster, villages with at least 500 residents and that included or was located near the
group head village were randomly selected per cluster. In villages with approximately 500 resi-
dents, all households were eligible for the survey. In larger villages, 150 households were
recruited in a clockwise spiral starting with the village head household, with multiple visits
made to schedule interviews. Written informed consent or assent was obtained for residents
aged 15 years and older in recruited households. Participants were interviewed on household
and sociodemographic characteristics, HIV service use, and sexual behavior. A random sample
(approximately 20%) received an HIV knowledge and attitudes module (Text A in S2 Text).
Clinic assistants at the 5 health facilities interviewed ART patients aged 15 years and older
to establish cluster eligibility for 6 months following the intervention. Population estimates for
cluster residents aged 15 years and older were obtained from village and facility registers and
used as the denominator for cumulative incidence of ART initiations.
Process indicators measuring HIVST coverage were assessed through the survey and
HIVST registers, which recorded sociodemographic information for residents collecting
HIVST kits. Adverse events related to HIVST were captured through the survey and classified
by severity [24].
Economic data on the total and unit costs of the intervention were collected from the pro-
vider perspective, with financial costs from expenditure records supplemented with full costs
from direct observations and interviews (Text B in S2 Text). Costs are reported in 2018 US
Dollars.
Planned outcome evaluation of a repeat community-led HIVST intervention [20] was not
completed due to delayed study initiation, leaving insufficient time between post-intervention
assessments. The study reported here had standalone outcomes and was not affected.
Sample size
The study was powered to detect a 20% absolute difference between study arms in the primary
outcome of lifetime HIV testing for adolescents [18]. We assumed 35% to 50% prevalence of
testing among adolescents in the SOC arm based on national estimates [21]. Fifteen group vil-
lage head clusters per arm with 50 adolescents of 250 residents per cluster provided 90% power
at a 5% significance level. We assumed a coefficient of variation (k) of 0.25 based on guidelines
for cluster-randomised trials [22]. The study was also powered to measure a difference in
recent HIV testing in older adults and men and cumulative ART initiations (S1 Text).
Statistical analysis
Analysis used intention-to-treat, that is participants within clusters were analysed based on
cluster assignment to study arms rather than individual-level exposure to the intervention.
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Outcomes were analysed at cluster level using established methods for cluster-randomised tri-
als with a small number of clusters [22]. Specifically, risk differences, mean differences, and
risk ratios for the intervention effect were calculated from cluster-level risks, means, and log
risks, respectively (S1 Text). Cluster-level summaries were then compared between arms with
a t test.
Using a 2-stage approach [22], effect estimates were adjusted for sex and age group a priori
and any imbalance between arms in adolescent covariates. To estimate the risk difference and
risk ratio, the first stage used logistic regression to adjust for confounding bias at the individual
level. Predicted risks were then summed at cluster level and used to calculate the difference
and ratio of observed and predicted values. A log transformation was applied to summaries as
appropriate. The second stage used a t test to compare covariate-adjusted summary values
between arms. To calculate the mean difference, similar procedures were applied using linear
regression in the first stage.
A priori subgroup analysis compared the primary outcome by sex and age group (15 to 17
years, 18 to 19 years). Post hoc analysis compared cumulative incidence of ART initiation by
first and last 3-month period. Statistical analysis used Stata version 14.0.
Ethical considerations
The study is registered with ClinicalTrials.gov, NCT03541382. Ethical approvals were granted
by the University of Malawi College of Medicine (P.01/18/2332), London School of Hygiene &
Tropical Medicine (14761), and WHO (STAR-comm led CRT-Malawi). The study is part of
the Unitaid/Population Services International HIV Self-Testing Africa Initiative (STAR)
[http://hivstar.lshtm.ac.uk/].
Results
The study population included 44,543 residents in 15 community-led HIVST clusters and
39,806 residents in 15 SOC clusters. The intervention was delivered from October 5, 2018 to
January 17, 2019 by 157 community health action group members (cluster mean 10.5) and 190
community volunteers (cluster mean 12.7). Overall, 24,316 HIVST kits (cluster mean 1,621)
were distributed, with 47.2% (n = 11,472) of kits distributed to men.
Outcomes were measured from December 5, 2018 to March 30, 2019 for the post-interven-
tion survey and to July 31, 2019 for facility data collection. Fig 2 shows the trial flow diagram.
The survey included 90.2% (3,960/4,388) and 89.2% (3,920/4,394) of listed participants,
respectively, in the community-led HIVST and SOC arms. Adolescent participation rates were
similar at 90.2% (910/1,002) in the community-led HIVST arm and 86.4% (867/1,004) in the
SOC arm.
Participant characteristics are summarised in Table 1. Overall, the proportion of men was
39.0% (3,072/7,880), which was below expected [21] with 84.6% (1,577/1,863) and 82.4%
(1,495/1,814) responding in the community-led HIVST and SOC arms, respectively.
Most participants obtained primary-level education or below. The majority were married and
reported a sexual partner. Characteristics were well balanced by arm, though differences in liter-
acy, religion, ethnicity, and self-reported health status were observed for adolescents (Table 2).
Primary and secondary outcomes
Lifetime HIV testing among adolescents was higher in the community-led HIVST arm (84.6%,
770/910) than the SOC arm (67.1%, 582/867), with adjusted risk difference (RD) of 15.2%
(95% CI 7.5% to 22.9%; p< 0.001; Table 3 and Table A in S2 Text and Fig A in S2 Text). There
was strong evidence that the effect of the intervention differed by age group (p-value for
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interaction = 0.02), with a more pronounced difference among 15 to 17 year olds (adjusted RD
21.5%, 95% CI 10.4% to 32.6%; p< 0.001) than 18 to 19 year olds (adjusted RD 10.8%, 95% CI
4.3% to 17.3%; p = 0.002). Lifetime testing was also higher for boys (adjusted RD 20.5%, 95%
CI 10.7% to 30.3%; p< 0.001) than girls (adjusted RD 11.1%, 95% CI 2.8% to 19.4%; p = 0.01;
p-value for interaction = 0.06).
Recent HIV testing (in the last 3 months) among older adults was higher in the community-
led HIVST arm (74.5%, 869/1,166) than the SOC arm (31.5%, 350/1,111), with adjusted RD of
42.1% (95% CI 34.9% to 49.4%; p< 0.001). The proportion of recently tested men was 74.6%
(1,177/1,577) in the community-led HIVST arm and 33.9% (507/1,495) in the SOC arm
(adjusted RD 40.2%, 95% CI 32.9% to 47.4%; p< 0.001). Knowledge of the preventive benefits of
HIV treatment and HIV testing stigma measures showed no differences between arms (Table 3).
Cumulative 6-month incidence of ART initiation was, respectively, 305.3 and 226.1 per
100,000 population in the community-led HIVST and SOC arms (RD 72.3, 95% CI −36.2 to
180.8; p = 0.18). In post hoc analysis, cumulative incidence in the 3-month post-intervention
period was, respectively, 186.3 and 93.0 per 100,000 population in the community-led HIVST
and SOC arms, with a larger effect in the first 3 months (RD 97.7, 95% CI 33.4 to 162.1;
p = 0.004) than the last 3 months (RD −10.7, 95% CI −80.5 to 59.2; p = 0.76; p-value for
interaction = 0.02).
In exploratory analyses, the intervention increased HIV testing in 3-month, 12-month, and life-
time periods, overall and among defined subgroups, and mutual knowledge of HIV status between
sexual partners (adjusted RD 14.1%, 95% CI 8.6% to 19.5%; p< 0.001; Table A in S2 Text).
Fig 2. Trial flow diagram. Flow diagram of the cluster-randomised trial.
https://doi.org/10.1371/journal.pmed.1003608.g002
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Table 1. Comparison of population characteristics by study arm.
Community-led HIVST SOC
n (%) n (%)
Household characteristics (N = 1,994) (N = 2,015)
Adults (median/range)� 2 (0–8) 2 (0–10)
Children (median/range)� 1 (0–1) 1 (0–1)
Household wealth index†
Lowest 368 (20.3%) 341 (18.6%)
Second 353 (19.4%) 395 (21.6%)
Third 361 (19.9%) 362 (19.8%)
Fourth 358 (19.7%) 373 (20.4%)
Highest 375 (20.7%) 358 (19.6%)
Individual characteristics (N = 3,960) (N = 3,920)
Male 1,577 (39.8%) 1,495 (38.1%)
Age (median/range) 29 (15–96) 29 (15–98)
Age group
15–19 years 910 (23.0%) 867 (22.1%)
20–24 years 631 (15.9%) 675 (17.2%)
25–39 years 1,253 (31.6%) 1,267 (32.3%)
�40 years 1,166 (29.4%) 1,111 (28.3%)
Marital status‡
Married or living together 2,428 (61.3%) 2,467 (62.9%)
Separated, divorced, or widowed 612 (15.5%) 542 (13.8%)
Never married 918 (23.2%) 910 (23.2%)
Educational attainment§
None 1,730 (43.7%) 1,764 (45.0%)
Primary 1,902 (48.0%) 1,838 (46.9%)
Secondary or higher 328 (8.3%) 317 (8.1%)
Literate|| 2,196 (55.5%) 2,066 (52.7%)
Muslim 2,840 (71.7%) 3,008 (76.7%)
Ethnicity
Yao 2,778 (70.2%) 2,942 (75.1%)
Ngoni 546 (13.8%) 443 (11.3%)
Other 636 (16.1%) 535 (13.6%)
Resident in the last 2 months 3,877 (97.9%) 3,830 (97.7%)
Self-rated health status¶
Very good 1,546 (39.1%) 1,314 (33.5%)
Good 1,738 (43.9%) 1,810 (46.2%)
Fair 338 (8.5%) 389 (9.9%)
Poor 337 (8.5%) 407 (10.4%)
Reported current sexual partner�� 2,875 (72.6%) 2,931 (74.8%)
Circumcised (for men)†† 1,335 (84.9%) 1,285 (86.0%)
HIVST, HIV self-testing; SOC, standard of care.
�32 missing values in the community-led HIVST arm and 8 missing values in the SOC arm.
†179 missing values in the community-led HIVST arm and 186 missing values in the SOC arm.
‡2 missing values in the community-led HIVST arm and 1 missing value in the SOC arm.
§1 missing value in the SOC arm.
||1 missing value in the community-led HIVST arm.
¶1 missing value in the community-led HIVST arm.
��1 missing value in the SOC arm.
††5 missing values in the community-led HIVST arm.
https://doi.org/10.1371/journal.pmed.1003608.t001
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Process outcomes
Self-reported HIVST uptake was 74.7% (2,956/3,960) in the community-led HIVST arm, rang-
ing from 68.5% in older men to 84.7% in young women (20 to 24 years), and 3.7% (145/3,920)
in the SOC arm (Table 4 and Fig B in S2 Text). The proportion of participants aware of HIVST
was 95.3% (3,771/3,960) and 32.4% (1,268/3,920) in the community-led HIVST and SOC
arms, respectively.
Of 2,956 self-testers in the community-led HIVST arm, most obtained HIVST kits through
primary distribution from community health groups (93.9%, n = 2,775). Only 4.4% (n = 130)
received HIVST kits through secondary distribution from family members.
The majority of kits were obtained at the home of the participant (80.9%, n = 2,392) fol-
lowed by the home of community health volunteers (7.4%, n = 220). Further, 10.4% (n = 306)
reported no previous HIV testing and 2.4% (n = 70) reported an HIV-positive result, of whom
Table 2. Comparison of characteristics for adolescents (15–19 years) by study arm.
Community-led HIVST SOC
n (%) n (%)
Individual characteristics (N = 910) (N = 867)
Male 387 (42.5%) 381 (43.9%)
Age (median/range) 18 (15–19) 18 (15–19)
Age group
15–17 years 400 (44.0%) 384 (44.3%)
18–19 years 510 (56.0%) 483 (55.7%)
Marital status�
Married or living together 138 (15.2%) 147 (17.0%)
Separated, divorced, or widowed 34 (3.7%) 20 (2.3%)
Never married 738 (81.1%) 699 (80.7%)
Educational attainment
None 239 (26.3%) 262 (30.2%)
Primary 604 (66.4%) 552 (63.7%)
Secondary or higher 67 (7.4%) 53 (6.1%)
Literate 667 (73.3%) 577 (66.6%)
Muslim 672 (73.8%) 686 (79.1%)
Ethnicity
Yao 665 (73.1%) 684 (78.9%)
Ngoni 126 (13.8%) 88 (10.1%)
Other 119 (13.1%) 95 (11.0%)
Resident in the last 2 months 879 (96.6%) 844 (97.3%)
Self-rated health status†
Very good 416 (45.8%) 328 (37.8%)
Good 406 (44.7%) 449 (51.8%)
Fair 46 (5.1%) 42 (4.8%)
Poor 41 (4.5%) 48 (5.5%)
Reported current sexual partner 389 (42.7%) 390 (45.0%)
Circumcised (for men) 340 (87.9%) 346 (90.8%)
HIVST, HIV self-testing; SOC, standard of care.
�1 missing value in the SOC arm.
†1 missing value in the community-led HIVST arm.
https://doi.org/10.1371/journal.pmed.1003608.t002
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40.0% (n = 28) were newly identified and 11.4% (n = 8) were previously diagnosed and not on
treatment. Self-reported ART initiation was 58.3% (21/36).
Table 3. Primary and secondary outcomes by study arm.
Community-led
HIVST
SOC Risk or mean
difference (95% CI)
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Knowledge of the preventive
benefits of HIV treatment��
15.0 14.7 0.3 (−0.6–1.3) 0.51 0.4 (−0.4–1.3) 0.29
HIV testing stigma†† 7.4 7.6 −0.2 (−0.6–0.2) 0.36 −0.2 (−0.5–0.2) 0.37
ART, antiretroviral therapy; GM, geometric mean (of cluster-level proportions); HIVST, HIV self-testing; k, coefficient of variation in group village head-defined
clusters; SOC, standard of care.
�Analysis adjusted for sex, age group, literacy, religion, ethnicity, and health status. Analysis among adolescents defines levels of age group as 16–17 years and 18–19
years. Analysis among adults�40 years defines levels of age group as 40–49 years and�50 years. Analysis among men adjusts for the same covariates except for sex.
†p-Value for interaction, p = 0.02.
‡p-Value for interaction, p = 0.06.
§Testing in the last 3 months was ascertained based on the most recent test date. If the month of the test date was not reported, we counted the test as being in the last 3
months if the test date was in 2018 for interview dates in 2018 or if the test date was in 2018 or 2019 for interview dates in 2019. 113 and 156 participants in the
community-led HIVST and SOC arms, respectively, did not report month data. We conducted a sensitivity analyses where test dates with missing months were not
counted as being in the last 3 months. Among adults�40 years, community-led HIVST: 72.0% (839/1,166), SOC: 27.0% (300/1,111); adjusted RD 43.7%, 95% CI 36.0%–
51.5%; p< 0.001. Among men, community-led HIVST: 72.0% (1,135/1,577), SOC: 30.7% (459/1,495); adjusted RD 40.4%, 95% CI 32.7%–48.0%; p< 0.001.
||Denominator for ART initiations is the estimated cluster population of adults�15 years, which was estimated using village and health facility registers and the
proportion of adults reported in household enumeration.
¶Post hoc analysis. p-Value for interaction, p = 0.02.
��N = 1,925, with 30 missing values. Score is the sum of 5 questions using 5-point likert scale, with range of 5–25 (low to high knowledge).
††N = 1,929, with 26 missing values. Score is the sum of 6 questions using 3-point likert scale, with range of 3–18 (low to high stigma).
https://doi.org/10.1371/journal.pmed.1003608.t003
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Adverse events related to HIVST were reported by 0.6% of participants (18/2,955) and clas-
sified by severity [24]. Reports included forced self-testing or results disclosure (moderate
grade) and one case of physical harm (moderate to severe grade).
Costs
Total provider cost of community-led HIVST was US$138,624, with a mean cost of US$ US
$5.70 per HIVST kit distributed (Table B in S2 Text). Unit costs were US$241 per HIV–posi-
tive identified, US$602 per new HIV–positive identified, and US$468 per HIV–positive identi-
fied not on treatment.
Discussion
Community-led delivery of 7-day HIVST campaigns linked to HIV treatment and preven-
tion increased HIV testing in underserved subgroups. Lifetime testing increased by 15.2%
Table 4. Fidelity to community-led HIV self-testing intervention.
Community-led HIVST SOC
n (%) n (%)
(N = 3,960) (N = 3,920)
Heard of self-testing� 3,771 (95.3%) 1,268 (32.4%)
Ever self-tested† 2,956 (74.7%) 145 (3.7%)
Self-tested in the last 3 months‡ 2,919 (73.7%) 128 (3.3%)
For most recent self-test: (N = 2956)
Self-test distributor§ 2,775 (93.9%)
Community health volunteer 2,775 (93.9%)




Home of community health volunteer 220 (7.4%)
Other 343 (11.6%)





Harmed before or after self-testing‡‡ 18 (0.6%)
HIVST, HIV self-testing; SOC, standard of care.
�1 missing value in the community-led HIVST arm and 1 missing value in the SOC arm.
†1 missing value in the community-led HIVST arm.
‡1 missing value in the community-led HIVST arm.
§2 missing values in the community-led HIVST arm.
||1 missing value in the community-led HIVST arm.
¶1 missing value in the community-led HIVST arm.
��5 missing values in the community-led HIVST arm.
††40% (n = 28) were newly HIV–positive, 11.4% (n = 8) were previously diagnosed and not on treatment, 48.6%
(n = 34) were previously diagnosed and on treatment. Of 36 HIV–positive and not on treatment, 58.3% (n = 21)
initiated on antiretroviral therapy.
‡‡1 missing value in the community-led HIVST arm.
https://doi.org/10.1371/journal.pmed.1003608.t004
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for adolescents, with more pronounced differences among younger adolescents and boys.
Recent testing increased by 42.1% for older adults and by 40.2% for men. Mutual knowl-
edge of HIV status between sexual partners also improved. Cumulative incidence of ART
initiation per 100,000 population apparently increased 3 months post-intervention, with
186.3 residents treated in the community-led HIVST arm compared with 93.0 residents
treated in the SOC arm. Difference in ART initiations between arms was not found for the
predefined 6-month period. The intervention also achieved 74.7% HIVST uptake with lim-
ited adverse events and at US$5.70 per HIVST kit distributed. Our study provides evidence
of an effective, safe, and affordable community strategy that rapidly achieved high impact
and coverage at low cost and could be scaled in priority settings to meet and maintain HIV
elimination goals.
To our knowledge, this is the first randomised trial to assess the impact of community-led
delivery of HTS, which was recently enabled by the introduction of HIVST. This is also one of
the few studies to report high coverage of HIV testing among subgroups with substantial undi-
agnosed HIV infection. Community participation has long been advocated as fundamental to
primary healthcare and an approach that could increase coverage and efficiency of health pro-
grammes, improve outcomes, enhance the capacity of communities to address ill-health, and
contribute to the sustainability of community health programmes [10]. We used participatory
methods to engage established community health groups in designing and implementing
HIVST campaigns adapted to their respective contexts. Our study builds on “top-down” com-
munity-based HIV testing and self-testing [18, 19] and “bottom-up” community-led demand
creation for HIV services [12,15] by using a community-led HIVST model. Future iterations
of this intervention could engage groups over time to provide repeat or multidisease services,
including interventions to address malaria, tuberculosis, and other priority disease areas [25].
With the COVID-19 epidemic, community-led disease control programmes have potential to
contribute to surveillance and early detection, reporting, and management. HIVST may also
enable ongoing provision of HIV testing as routine HIV services are disrupted and reduce
demand on healthcare workers to provide in-person HIV testing [26].
We found that community-led HIVST can lead to high coverage and effective targeting,
with our study reporting substantially higher HIVST uptake from a community-led approach
than a previous study of door-to-door HIVST [18]. Uptake was consistent across adolescents,
older adults, and men. In contrast, vertical distribution of HIVST kits by community-based
distribution agents achieved 42.5% uptake across a 12-month period in Malawi [18]. Uptake
may be driven by successful context-informed planning, trust between community health
groups and community members, and the value and novelty of HIVST among HIV-prevalent
communities. The intervention also had minimal adverse events, alleviating safety concerns
around decentralising management of HIVST implementation [16]. Further, our results may
be applicable to high HIV prevalence settings in sub-Saharan Africa with similar cadres of
community health workers and volunteers.
We showed increased lifetime and recent HIV testing in adolescents, especially younger
adolescents and boys, older adults, and men, with prevalence of undiagnosed HIV dispropor-
tionately concentrated in these subgroups. Mutual knowledge of HIV status between sexual
partners also increased. The intervention effect, while slightly lower than assumed for sample
size calculations, was achieved against a SOC that included a high saturation of HIV services,
with Mangochi a priority district for the Ministry of Health. Diagnosis of recent HIV infection
is critical for HIV prevention, with our study reinforcing the importance of community strate-
gies in reaching underserved subgroups [7]. Further, the impact attained within a short period
of time makes community-led HIVST a promising candidate for national HIV programmes to
consider for periodic implementation to reach underserved subgroups.
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Community-led HIVST had an immediate impact on ART initiation 3 months post-inter-
vention, though the effect diminished at 6 months. Population-level impact was measured
even as the post-intervention survey reported that 1.2% of self-testers were newly HIV–posi-
tive or previously diagnosed but not on treatment, underscoring the potential for HIVST to
influence ART demand. The intervention involved engaging government CHWs and health
facilities to facilitate linkage to routine HIV services, likely contributing to successful referrals.
However, self-reported ART initiation was 58.3% at follow-up. Optimising timely linkage to
HIV treatment and prevention services is essential to maximise the health benefits from HIV
testing and self-testing [27]. Neither VMMC nor preexposure prophylaxis were available at
primary care level during the study, so we were unable to evaluate uptake of these services as
intended. Further, despite providing training and materials to community volunteers on HIV
prevention messages, the intervention did not improve knowledge of the preventive benefits of
HIV treatment. The absence of effect may reflect insufficient discussion on the topic or diffi-
culties conveying HIV risk reduction concepts.
Our analysis reported average cost of US$5.70 per HIVST kit distributed, which was lower
than the cost of door-to-door HIVST models in nearby rural districts (2017 US$8.15) and
urban Blantyre (2014 US$8.78) [28,29]. Average costs of community-based HTS in sub-Saha-
ran Africa were similar [7]. Community health programmes are important for epidemic pre-
paredness and management but can be costly to implement [9]. A community-led approach to
HIVST is likely to realise significant economies of scale, with potential cost savings when com-
munity health groups are mobilised nationally and recurrently by Ministries of Health in non-
research settings. Economies of scope can also lead to greater efficiency by implementing
HIVST within a package of interventions addressing a broader set of conditions, including
through the use of self-care products. Further, we found that the cost per HIV–positive identi-
fied through HIVST was US$241 to US$602, with modelling studies suggesting a cost-effec-
tiveness threshold of US$315 per new HIV diagnosis [4]. Further cost reductions and uptake
among undiagnosed, untreated HIV–positive persons or high HIV risk persons linking to
HIV prevention would ensure greater probability of community-led HIVST as a cost-effective
strategy.
Our study had multiple limitations. Due to the pragmatic nature of the intervention, there
was some contamination of HIVST in the SOC arm, although reported events were nominal.
The study design did not allow us to isolate the effects of specific intervention components,
including the use of participatory methods and introduction of HIVST. Primary and second-
ary outcomes on HIV testing were self-reported and subject to misreporting due to recall or
social desirability bias, including overreporting in the community-led HIVST arm following
exposure to the intervention. We had a small number of clusters per arm and aimed to mimi-
mise bias through randomisation of clusters, using restriction of factors likely to be associated
with the outcome, and adjustment for imbalances between arms in individual characteristics.
However, we did not measure primary and secondary outcomes in a baseline sample and
adjust for baseline HIV testing. Our sampling frame may have included households that had
better access to the HIVST intervention due to their location, with potential overestimation of
the intervention effect. However, the effect size was relatively large, and our conclusions would
have likely remained unchanged. The survey included fewer men than expected with almost
one-fifth of eligible men not found. Implementation occurred within a controlled research set-
ting as part of a mature HIVST programme that had been operating since 2015, potentially
affecting the generalisability of our costs. Adverse events were reported in the survey, with fol-
low-up to obtain details not feasible. We also did not evaluate accuracy of HIVST, which was
previously shown to be high in rural settings when given optimised instructional materials and
brief demonstrations [30].
PLOS MEDICINE A cluster-randomised trial of community-led delivery of HIV self-testing
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003608 May 11, 2021 15 / 18
Community-led delivery of 7-day HIVST campaigns linked to HIV treatment and preven-
tion was effective in increasing HIV testing in adolescents, older adults, and men and mutual
knowledge of HIV status between sexual partners. Population-level ART initiation apparently
increased within a 3-month period but showed no difference at 6 months. Community-led
delivery of HIVST was safe and associated with higher uptake and lower costs compared with
previous evaluations of vertical community-based HIV testing and self-testing. Given evidence
of high population impact and coverage rapidly realised at low cost, community-led HIVST
shows much promise as an effective, safe, and affordable strategy, while entrusting communi-
ties with leading solutions for disease control. This approach could enable community HIV
testing in high HIV prevalence settings and demonstrates potential for economies of scale and
scope.
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